Cerus (CERS)
(Delayed Data from NSDQ)
$1.84 USD
-0.01 (-0.54%)
Updated May 24, 2024 04:00 PM ET
3-Hold of 5 3
C Value C Growth A Momentum B VGM
Brokerage Reports
0 items in cart
Cerus Corporation [CERS]
Reports for Purchase
Showing records 21 - 40 ( 69 total )
Company: Cerus Corporation
Industry: Medical - Products
Company: Cerus Corporation
Industry: Medical - Products
LIFE SCIENCES AND HEALTH CARE-The Week Ahead in Life Sciences - Upcoming Events for the Week of Dec 15
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Cerus Corporation
Industry: Medical - Products
Company: Cerus Corporation
Industry: Medical - Products
Company: Cerus Corporation
Industry: Medical - Products
3Q14 Top Line Edges Higher - EPS So-So - Guidance Disappoints - FDA Process & Pipelines On Track - Calendar Still Interesting - PT to $6 - Maintain OP
Provider: WEDBUSH SECURITIES INC.
Analyst: KHURSHID Z
Company: Cerus Corporation
Industry: Medical - Products
3Q14 Preview - Expecting In-line Sales - EU Macro Sounding Better - FDA Dialogue & Gates Foundation Commentary Could Be Interesting - Maintain OP
Provider: WEDBUSH SECURITIES INC.
Analyst: KHURSHID Z
Company: Cerus Corporation
Industry: Medical - Products
Thoughts on Ebola Flare-Up - Recent Cost Savings Abstract Is Encouraging
Provider: WEDBUSH SECURITIES INC.
Analyst: KHURSHID Z
Company: Cerus Corporation
Industry: Medical - Products
Company: Cerus Corporation
Industry: Medical - Products
Company: Cerus Corporation
Industry: Medical - Products
2Q14 Progress as Sales Edge Past Consensus - FDA Reviews Appear On Track
Provider: WEDBUSH SECURITIES INC.
Analyst: KHURSHID Z
Company: Cerus Corporation
Industry: Medical - Products
2Q14 Preview - Residual Distributor Impact is Entirely Possible - That Said, Direct Business & Back-Half Setup into 2015 is Interesting - Maintain OP
Provider: WEDBUSH SECURITIES INC.
Analyst: KHURSHID Z
Company: Cerus Corporation
Industry: Medical - Products
Post NDR Update - Slightly More Encouraged on Direct Sales Transition - Still Somewhat Skeptical on 2014 Guidance - Maintain OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: KHURSHID Z
Company: Cerus Corporation
Industry: Medical - Products
Post NDR Update - Slightly More Encouraged on Direct Sales Transition - Still Somewhat Skeptical on 2014 Guidance - Maintain OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: KHURSHID Z
Company: Cerus Corporation
Industry: Medical - Products
Company: Cerus Corporation
Industry: Medical - Products
1Q14 Preview - Not Expecting Heroic Numbers Given the EU Distributor Transition
Provider: WEDBUSH SECURITIES INC.
Analyst: KHURSHID Z
Company: Cerus Corporation
Industry: Medical - Products
4Q13 Results Weak as EU Distributors Underperform - US Platelet Approval Delayed Slightly - LT Thesis Intact - Trimming PT
Provider: WEDBUSH SECURITIES INC.
Analyst: KHURSHID Z
Company: Cerus Corporation
Industry: Medical - Products
Company: Cerus Corporation
Industry: Medical - Products
Expecting Softer 4Q13 Sales Due to Modeling Nuances and Lumpiness - Upping PT
Provider: WEDBUSH SECURITIES INC.
Analyst: KHURSHID Z
Company: Cerus Corporation
Industry: Medical - Products
Encouraged by 1st US Commercial Hires - Brings Insight into ARC, Largest Potential Customer - Bullish Signal for FDA Dialogue, as Well - Reaffirm OP
Provider: WEDBUSH SECURITIES INC.
Analyst: KHURSHID Z
Company: Cerus Corporation
Industry: Medical - Products
Encouraged by 1st US Commercial Hires - Brings Insight into ARC, Largest Potential Customer
Provider: WEDBUSH SECURITIES INC.
Analyst: KHURSHID Z